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Summary
 
Peripheral tolerance mechanisms normally prevent delivery of T cell help to anergic self-reac-
tive B cells that accumulate in the T zones of spleen and lymph nodes. Chronic exposure to
self-antigens desensitizes B cell antigen receptor (BCR) signaling on anergic B cells so that they
are not stimulated into clonal expansion by CD4
 
1
 
 T cells but instead are eliminated by Fas
(CD95)-induced apoptosis. Because a range of BCR-induced signals and responses are re-
pressed in anergic B cells, it is not known which of these are critical to regulate for Fas-medi-
ated peripheral tolerance. Display of the costimulatory molecule, B7.2 (CD86), represents a
potentially important early response to acute BCR engagement that is poorly induced by anti-
gen on anergic B cells. We show here that restoring B7.2 expression on tolerant B cells using a
constitutively expressed B7.2 transgene is sufficient to prevent Fas-mediated deletion and to
trigger extensive T cell–dependent clonal expansion and autoantibody secretion in the pres-
ence of specific T cells. Dysregulated expression of B7.2 on tolerant B cells caused a more ex-
treme reversal of peripheral tolerance than that caused by defects in Fas or Fas ligand, and re-
sulted in T cell–dependent clonal expansion and antibody secretion comparable in magnitude
to that made by foreign antigen-specific B cells. These findings demonstrate that repression of
B7.2 is critical to eliminate autoreactive B cells by Fas in B cell–T cell interactions. The possi-
ble role of B7.2 dysregulation in systemic autoimmune diseases is discussed.
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1
 
 T cells, to initiate humoral immune responses
against foreign antigens and simultaneously avoid au-
toimmunity, must selectively help foreign antigen–reactive
but not self-reactive B cells. Clonal deletion of self-reactive
T and B cells in the thymus and bone marrow provides
only a partial bulwark against T cell–dependent autoanti-
body production, because a significant number of self-reac-
tive T and B cells are exported to secondary lymphoid
tissues. Once they reach the spleen and lymph nodes, inter-
action between self-reactive B and T cells must be con-
trolled by peripheral tolerance mechanisms. Anergic B
cells, recognizing model self-antigens or nuclear autoanti-
gens that are prototypic targets in systemic lupus, concen-
trate as short-lived emigrants in the outer T zones adjacent
to B cell–rich follicles in the spleen and lymph nodes (1–3).
Paradoxically, this site appears to offer the greatest chance
of interacting with Th cells. The Fas ligand (FasL)/Fas
(CD95/APO-1)
 
1
 
 pathway plays a critical role in preventing
delivery of help to this class of autoreactive B cells (4–8).
During the early phases of anergic B cell–T cell interaction
in vivo, CD40L on the T cell signals the B cell to elevate
Fas expression and become sensitive to the apoptotic effects
of FasL on the T cell (8). When the Fas gene is mutated, T
cell–dependent activation of this class of self-reactive B
cells cannot be aborted by this mechanism, and the anergic
B cells gradually come to be triggered into high-rate au-
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; CTLA4, cy-
totoxic lymphocyte–associated antigen 4; HEL, hen egg lysozyme;
HPRT, hypoxanthine phosphoribosyltransferase; L, ligand; PI, propidium
iodide; RT, reverse transcription; tg, transgenic.
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toantibody secretion (4, 6, 7) and to form large clones of
autoantibody-producing cells in the T zones (5).
Signaling by the B cell antigen receptor (BCR) regulates
whether B cells proliferate or undergo Fas (CD95)-induced
apoptosis when they present antigen to CD4
 
1
 
 T cells in
secondary lymphoid organs (6, 8–12). Acute BCR signal-
ing during exposure to foreign antigens promotes clonal
expansion and protects foreign-specific B cells against death
triggered by FasL on the T cell. In anergic self-reactive B
cells, BCR signaling is desensitized and qualitatively altered
by chronic exposure to self-antigens, so that the nuclear
factor of activated T cells (NFAT) and extracellular signal–
regulatory kinase (ERK) pathways continue to be stimu-
lated but the nuclear factor 
 
k
 
B and c-Jun NH
 
2
 
-terminal ki-
nase (JNK) signaling pathways are uncoupled from the
BCR (12, 13). This modulation of BCR signaling allows
the FasL/Fas pathway to selectively abort proliferation of
self-reactive B cells, thus focusing T help onto foreign-spe-
cific B cells (6, 8). Because a range of signaling pathways
and early responses to BCR signaling are repressed or ab-
sent in self-tolerant (anergic) B cells (12, 13), it is not
known which must be regulated to allow Fas-mediated pe-
ripheral tolerance.
Surface display of the costimulatory molecule, B7.2
(CD86), is one of the early responses to acute BCR signal-
ing that is repressed in self-tolerant B cells (2, 12, 14–18).
Tolerant B cells present antigen to primary T cells effec-
tively, but cannot stimulate cytokine secretion in vitro un-
less the poor display of B7.2 is compensated by adding a
stimulatory antibody to CD28, a receptor for B7.2 that is
displayed constitutively on T cells (15). CD28 transmits
signals that synergize with the TCR for T cell activation
and cytokine secretion (18). Antibody blocking and gene
knockout experiments have established that B7.2 is impor-
tant for initiating humoral immune responses to foreign an-
tigens and for humoral autoimmunity (18–20). Although
these experiments do not resolve whether B7.2 functions
during activation of Th cells by dendritic cells, during T
cell–B cell interactions, or both, they highlight the poten-
tial importance of repressing B7.2 on self-tolerant B cells.
To test the significance of the repressed B7.2 response to
antigen on tolerant B cells, we describe here the effects of
selectively restoring B7.2 expression on these cells using a
constitutively expressed B7.2 transgene (21). Dysregulated
expression of B7.2 on self-tolerant B cells did not interfere
with desensitization of BCR signaling, but in the presence
of autoantigen-specific T cells, it was sufficient to prevent
their Fas-mediated deletion and to trigger extensive clonal
expansion and autoantibody secretion. The reversal of pe-
ripheral tolerance induced by B7.2 dysregulation was much
more extreme than the reversal caused by defects in Fas or
FasL, and resulted in T cell–dependent clonal expansion
and antibody secretion comparable in magnitude to that
made by foreign antigen-specific B cells. These findings
demonstrate that repression of B7.2 is critical to eliminate
autoreactive B cells by Fas in B cell–T cell interactions in
vivo. Based on these results, we suggest that failure to re-
press B7.2 on B cells may be equally or more important as
 
an inherited or acquired component of systemic autoim-
mune diseases than defects in the Fas pathway itself.
 
Materials and Methods
 
Mice.
 
Mice carrying a transgene for B7.2 (line 7 in reference
21) were crossed with C57BL6/J hen egg lysozyme (HEL)/Ig
 
HEL
 
double-transgenic mice (ML5/MD4-tg [22]) that had been previ-
ously crossed to B10.Br and selected for H-2k homozygosity.
Blood from the resulting offspring was screened by FACS
 
Ò
 
 to de-
termine which combination of transgenes they carried. Because
the MD4 Ig
 
HEL
 
 transgene and the H-2 complex are closely linked
on chromosome 17 (
 
z
 
1 cM apart), Ig
 
HEL
 
-tg mice were H-2k/b
heterozygotes. Wild-type and FasL-deficient non-tg or TCR-tg
mice were bred as described (8). T cells heterozygous for the 
 
gld
 
mutation of FasL were used because they develop in a nonauto-
immune background but fail to eliminate B cells by Fas in the
short-term adoptive transfer assays used here (6, 8). This failure is
perhaps due to formation of trimers which consist of both mutant
and wild-type FasL and have limited function. Recipient mice for
adoptive transfers were non-tg or ML5 HEL-tg (C57BL6/J 
 
3
 
B10.Br)F1 animals. Donor and recipient mice were between 6
and 20 wk of age. Sexes were matched as much as possible, al-
though no difference was observed between male and female
mice in the adoptive transfer assays described. Mice were MHC
matched in all experiments.
 
Adoptive Transfers.
 
B220
 
1
 
 B cells and CD4
 
1
 
 T cells were pu-
rified as described previously (8). 1–3 
 
3
 
 10
 
6
 
 B220
 
1
 
 B cells and
3–6 
 
3
 
 10
 
5
 
 CD4
 
1
 
 T cells were mixed on ice and injected via the
lateral tail vein into sublethally irradiated (750 cGy) recipient mice.
5 d after adoptive transfer, recipient mice were killed, and spleen
cell suspensions were made by passing through a metal sieve. The
cells were then counted by hemocytometer and suspended to ap-
propriate concentrations for flow cytometric analysis or spot ELISA
to determine the frequency of anti-HEL–secreting cells (8).
 
Flow Cytometry.
 
Cells were analyzed with a FACScan
 
Ò
 
 (Bec-
ton Dickinson, Mountain View, CA) as described (6). The fol-
lowing antigens and antibodies were used: B220, RA3-6B2–
FITC or –PE (Caltag Laboratories, Inc., South San Francisco,
CA); IgM
 
a
 
, RS3.1-FITC; Fas, Jo2-PE (PharMingen, San Diego,
CA); B7.2, GL1-PE (PharMingen); CD69, H1.2F3-FITC (Phar-
Mingen); HEL, HyHEL9-TRIcolor (custom conjugation; Caltag
Laboratories, Inc.); Syndecan, 281.2-biotin followed by streptavidin-
CyChrome (PharMingen); and OX40, OX40L–human Ig fusion
protein or control human Ig followed by goat anti–human Ig-PE
(gift of Dr. Wayne Godfrey, University of California at San Fran-
cisco, San Francisco, CA). Cell numbers for each experiment
were determined by multiplying the frequency of B220
 
1
 
IgM
 
a
 
1
 
HEL-binding cells by the cell count as determined by hemocy-
tometer.
 
Western Blots.
 
Western blots were performed as described
(12).
 
In Vitro
 
 
 
Cultures and Competitive Reverse Transcription PCR.
 
Cells were cultured at 37
 
8
 
C, 5% CO
 
2
 
 at 1 or 2 
 
3
 
 10
 
6
 
 cells/ml to-
gether in 1 ml or 200 
 
m
 
l complete RPMI in 24- or 96-well
round-bottomed plates (Corning Glass Works, Corning, NY),
respectively. The anti-CD40 antibody, 1C10 (Southern Biotech-
nology Associates, Inc., Birmingham, AL), was used at 10 
 
m
 
g/ml,
and the anti-Fas antibody, Jo2, was used at 100 ng/ml. Cells were
harvested for FACS
 
Ò
 
 analysis, or total RNA was prepared with
Trizol (GIBCO BRL, Gaithersburg, MD) according to the man-
ufacturer’s instructions. Cell death was measured flow cytometri-
cally by propidium iodide (PI) exclusion, and specific killing was de- 
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termined by subtracting the percentage of PI
 
1
 
IgD
 
a
 
1
 
 cells in the
absence of Jo2 from the percentage of PI
 
1
 
IgD
 
a
 
1
 
 cells in the pres-
ence of Jo2 and dividing by 100, minus the percentage of
PI
 
1
 
IgD
 
a
 
1
 
 cells in the absence of Jo2. Total RNA from each sam-
ple was reverse transcribed (Superscript II; GIBCO BRL) with
oligo-dT (Pharmacia Biotech AB, Uppsala, Sweden) and subject
to competitive reverse transcription (RT)-PCR as described (23).
In brief, after reverse transcription, cDNA concentrations were
normalized by titration samples against a known concentration of
hypoxanthine phosphoribosyltransferase (HPRT) competitor plas-
mid. The normalized dilution of each sample cDNA was identi-
fied as that which gave equivalent HPRT PCR product to the
competitor plasmid. The differences in the amount of HPRT
PCR product generated for each sample were less than twofold.
PCR for HPRT was repeated at the normalized sample cDNA
dilutions, followed by PCR for IL-2, FasL, CD40L, and IL-4.
The sample cDNA PCR product sizes for HPRT, IL-2, IL-4,
FasL, and CD40L are 352, 247, 240, 350, and 443 bp, respec-
tively. The competitor PCR product sizes for IL-2, IL-4, FasL,
and CD40L are 320, 360, 510, and 603 bp, respectively. The
pPQRS plasmid containing the competitors for HPRT, IL-2,
and IL-4 was a gift of Sarah E. Townsend (John Curtin School of
Medical Research). The competitor plasmid for FasL and CD40L
was constructed as follows. An intron-spanning 350-bp fragment
of FasL and a 443-bp fragment CD40L mRNA were PCR am-
plified from activated T cells (AGT GTG GCC CAT TTA ACA
and ATG TTG ACA TAT AAA TGG TCA G for FasL, and
GAA GCC AAC AGT AAT GCA and TGC CAG CAT CAG
CCC TG for CD40L) and ligated to pBluescript (Stratagene Inc.,
La Jolla, CA) that had been cut with EcoRV (New England Bio-
labs, Inc., Beverly, MA) and incubated with dTTP (Pharmacia
Biotech AB) plus Taq DNA polymerase (Promega Corp., Madi-
son, WI) to generate pFasL and pCD40L. 160-bp fragments of
the HEL gene were PCR amplified from ML5-tg mice by prim-
ers with 5
 
9
 
 NdeI and 5
 
9
 
 AvrII adapter sites for FasL and CD40L,
respectively (GAA GAC ACA TAT GGA GCG TGA ACT
GCG CGA AGA and GCG GTT CCA TAT GTC GGT ACC
CTT GCA GCG GTT for FasL, and GCG CTG TCC TAG
GGA GCG TGA ACT GCG CGA AGA and GCT GCA GCC
TAG GTC GGT ACC CTT GCA GCG GTT for CD40L), and
inserted into FasL and CD40L on pFasL and pCD40L in unique
NdeI or AvrII sites, respectively, to generate pCFasL and pCCD40L.
 
Results
 
The B7.2 Transgene Does Not Interfere with B Cell Tolerance
to HEL.
 
To study the functional significance of the fail-
ure of self-tolerant B cells to display B7.2, transgenic mice
expressing high levels of B7.2 constitutively on B cells (line
7 in reference 21) were bred to mice carrying unlinked
transgenes encoding both anti-HEL Ig (Ig
 
HEL
 
) and HEL as
a soluble serum protein (22). This cross produced mice
with HEL-specific B cells that either had not previously
been exposed to HEL antigen (naive) or had been chroni-
cally exposed to HEL (tolerant). In both types of progeny,
half carried the B7.2 transgene (B7.2
 
1
 
 naive or tolerant)
and half did not. In mice that inherited the B7.2 transgene,
the constitutive level of B7.2 expressed on splenic B cells
was comparable to that normally induced on naive HEL-
specific B cells 6–20 h after acute exposure to HEL antigen
(Fig. 1 
 
a
 
, and data not shown). Mice which express the
B7.2 transgene alone have reduced and variable numbers of
B cells through an antigen-nonspecific T cell–mediated
mechanism (21). However, the additional presence of the
HEL and Ig
 
HEL
 
 transgenes suppressed this phenotype. Thus,
comparable numbers of B7.2
 
1
 
 or B7.2
 
2
 
 tolerant B cells
were present in the spleens of the two kinds of mice (3.44 
 
6
 
1.15 
 
3
 
 10
 
7
 
 IgD
 
1
 
 cells for B7.2
 
1
 
/HEL/Ig
 
HEL
 
 mice com-
pared with 2.33 
 
6
 
 1.22 
 
3
 
 10
 
7
 
 IgD
 
1
 
 cells for normal
B7.2
 
2
 
/HEL/Ig
 
HEL
 
 mice). Also, unlike B7.2
 
1
 
 B cells in the
absence of the Ig
 
HEL
 
 transgene, which are enlarged and ac-
tivated (21), B7.2
 
1
 
 tolerant B cells are small and resting
(Fig. 2 
 
b
 
, and data not shown).
B7.2
 
1
 
 tolerant B cells that had been chronically exposed
to self-antigen in HEL/Ig
 
HEL
 
-tg animals were tolerant to
HEL and could be rendered sensitive to killing through
Fas. Thus, the B7.2
 
1
 
 tolerant B cells selectively downregu-
lated surface IgM but not IgD similarly to tolerant B cells
lacking the B7.2 transgene (Fig. 1 
 
b
 
). The small difference
in percentage of IgM
 
high
 
IgD
 
high
 
 cells between the B7.2
 
1
 
and B7.2
 
2
 
 tolerant splenocytes in Fig. 1 
 
b
 
 was not repro-
ducible, and represents natural variation of IgM expression
on tolerant B cells presumably due to variation in blood
HEL concentration. The mean ratio of IgM
 
high
 
IgD
 
high
 
 to
IgM
 
low
 
IgD
 
high
 
 splenic B cells was found to be 18.6 
 
6
 
 5.6 in
Ig
 
HEL
 
-tg mice, 0.5 
 
6
 
 0.2 in HEL/Ig
 
HEL
 
-tg mice, and 0.4 
 
6
 
0.2 in B7.2
 
1
 
 HEL/Ig
 
HEL
 
-tg mice. Moreover, HEL antigen
induced CD69 only to low levels (Fig. 1 
 
c
 
), and was unable
to increase tyrosine phosphorylation of intracellular pro-
teins such as syk, lyn, Ig
 
a
 
, and Ig
 
b
 
 (Fig. 1 
 
d
 
) in tolerant B
cells regardless of B7.2 expression. Importantly, tolerant
and B7.2
 
1
 
 tolerant B cells were equally sensitive to Fas-
mediated cytotoxicity in vitro after CD40 stimulation (Fig.
1 
 
e
 
).
 
B7.2 Expression on Tolerant B Cells Switches Their Fate
from Clonal Elimination to Clonal Expansion.
 
The effect of
B7.2 on antigen-specific B–T cell interactions was analyzed
in vivo by purifying naive or HEL tolerant B cells either
with or without the B7.2 transgene, mixing them with pu-
rified CD4
 
1
 
 T cells from 3A9 HEL-specific TCR-tg mice
(15), and adoptively transferring the cell mixture into sub-
lethally irradiated recipient mice. The fate of the B cells
was then observed by flow cytometry to enumerate the
number and phenotype of the transferred B cells and by
spot ELISA to determine the number of B cells that had
differentiated to secrete transgene-encoded anti-HEL anti-
body (Figs. 2 and 3). As reported previously, tolerant B
cells lacking the B7.2 transgene were eliminated when
adoptively transferred with wild-type (
 
1
 
/1) TCR-tg T
cells (Fig. 2 a; references 6 and 8). This elimination was
mediated by Fas, as FasL-deficient gld/1 TCR-tg T cells
did not eliminate the tolerant B cells, but rather triggered
blastogenesis and limited proliferation (Fig. 2 b; references
6 and 8). TCR gld/1 cells were used as described previ-
ously (6, 8), because in the short-term assay used here, they
are as deficient in killing through Fas as gld/gld cells, but
can be obtained from donors that do not have overt immu-
nopathology. By contrast to the tolerant B cells lacking the
B7.2 transgene, tolerant B cells that constitutively ex-654 Repression of B7.2 on Autoreactive B Cells Prevents Autoimmunity
pressed high levels of B7.2 were not eliminated by antigen-
specific T cells (Figs. 2 a and 3 a), and instead the popula-
tion of transferred B7.21 tolerant B cells enlarged (Fig. 2 b),
upregulated IgM and Fas (Fig. 2, c and d), and increased in
number 20–100-fold (Fig. 2 a). Thus, although in the pres-
ence of antigen-specific gld/1 TCR-tg T cells, both B7.21
and control tolerant B cells were protected from elimina-
tion and acquired similarly activated phenotypes, clonal ex-
pansion was much greater in the B7.2-tg tolerant B cells.
Although observed in other experiments, the elimination
of B7.2-tg B cells by antigen-nonspecific T cells (21) did
not occur in the experiments presented here due to irradia-
tion of recipient animals and the low number of adoptively
transferred T cells.
B7.2 expression on tolerant B cells was sufficient to stim-
ulate extensive B cell proliferation when they were trans-
ferred with antigen-specific T cells into non-tg recipients,
but little or no secreted antibody was produced (compare
Fig. 3 a, top left and bottom left, and few cells differentiating
into Syndecan1 plasmablast cells in Fig. 3 b). To test if con-
tinuous exposure of the B and T cells to antigen was neces-
sary to promote antibody production, B and T cells were
adoptively transferred into HEL-tg recipients. As reported
previously (6), antigen exposure in the absence of T cell
help reduced B cell numbers to near background levels
(Fig. 3 a, top right). However, in the continuous presence of
antigen and antigen-specific T cells, proliferation of B7.21
tolerant B cells was greatly increased, and most of the cells
now differentiated into plasma cells, resulting in massive
autoantibody secretion (Fig. 3, a and b, right). Under these
conditions, only trace numbers of normal tolerant B cells
were stimulated to proliferate and differentiate into autoan-
tibody-secreting cells upon interaction with 1/1 or gld/1
TCR-tg cells (Fig. 3 a, right). It is possible that the small
number of normal tolerant B cells that successfully collabo-
rate with T cells in this way represent cells at the upper end
of the normal distribution of endogenous B7.2 on tolerant
cells (Fig. 1 a), which is comparable to the B7.2 levels in-
duced on naive cells or on B7.21 transgene–expressing
cells. The B7.2 transgene had little effect on proliferation
and antibody production by naive B cells (Fig. 3 a). The
number of antibody-forming cells generated by the B7.21
tolerant B cell–T cell mixture was 2,000-fold higher than
from tolerant B cells where B7.2 was repressed normally,
and was comparable to the number produced by naive B
cells under the same transfer conditions. Therefore, despite
the fact that HEL induces a range of acute BCR signaling
responses in the naive cells that are absent in tolerant B cells
(12–14), restoring expression of B7.2 alone was sufficient
to switch the fate of tolerant B cells from elimination to
maximal clonal expansion and differentiation into plasma-
blasts.
Expression of B7.2 on Tolerant B Cells Alters the Pattern of
Gene Induction in T Cells. In contrast to naive B cells stim-
ulated by foreign antigen, tolerant B cells have a selective
costimulatory deficit for T cell cytokine production in vitro
that can be reversed by antibody-mediated cross-linking of
CD28 (15). To examine whether B7.2 expression on toler-
ant B cells altered cytokine gene expression in collaborating
T cells, tolerant B cells with or without the B7.2 transgene
Figure 1. Antigen receptors are downregulated and desensitized normally on self-reactive B cells in B7.2-tg animals. (a) Spleen cells from IgHEL-tg
mice (naive), HEL/IgHEL double-tg mice (tolerant), and HEL/IgHEL/B7.2 triple-tg mice (B7.21 tolerant) were cultured in vitro with 50 ng/ml HEL for
17 h, and B cells were analyzed flow cytometrically for B7.2 expression (thick lines). Control cells were held on ice and analyzed in parallel (thin lines).
Cells cultured in vitro for 17 h in media alone stained comparably to control cells held on ice (data not shown). Similar results were obtained upon stim-
ulation with 500 ng/ml HEL. (b) Splenocytes from naive, tolerant, and B7.21 tolerant mice were analyzed flow cytometrically for transgene-encoded
surface IgMa and IgDa. (c) Splenocytes were stimulated and analyzed for CD69 expression as in a. Note that CD69 is induced to lower levels per cell on
B7.21 or B7.22 tolerant cells compared with naive cells. Similar results were obtained for both 50 and 500 ng/ml HEL. (d) Naive, tolerant, and B7.21
tolerant B cells were purified by selection on anti-B220 magnetic microbeads and stimulated for 3 min in vitro with 1 mg/ml HEL, and whole cell ly-
sates were fractionated by SDS-PAGE and transferred to a nitrocellulose membrane. The Western blot was probed with antiphosphotyrosine, and then
reprobed with a mixture of anti-Syk (gift of J. Roberts and A. Defranco, University of California at San Francisco) and anti-Lyn antibodies as a loading
control. (e) Splenocytes from two control tolerant HEL/IgHEL mice and one B7.21/HEL/IgHEL tolerant mouse were cultured in vitro for 0, 24, 48, or
72 h in 1C10 anti-CD40 antibody followed by an additional 5–6-h culture in the presence or absence of Jo2 anti-Fas antibody. Cell death was deter-
mined in triplicate cultures by flow cytometric analysis of uptake of the vital dye, PI, and positive staining for IgDa. Error bars indicate SD. Equivalent re-
sults were obtained with B220 in place of IgDa.655 Rathmell et al.
were cultured in vitro with CD41 T cells from non-tg or
TCR-tg mice, and total RNA was prepared and converted
to cDNA. The cDNAs were then normalized for HPRT
concentration so as to produce less than twofold differences
in HPRT PCR product when titrated against a known
concentration of an HPRT competitor. After 16 h in vitro
(Fig. 4 a), competitive PCR analysis showed that FasL
mRNA was comparably induced in cultures with HEL-
specific T cells (TCR) regardless of whether the tolerant B
cells expressed B7.2 or not. By contrast, IL-2 mRNA was
induced only in HEL-specific T cells cultured with B7.21
tolerant B cells. Notably, message for IL-4, which has been
previously been shown in vitro to rescue B cells from Fas-
mediated apoptosis (11, 24–26), was detectable in cultures
of HEL-specific T cells and B7.21 tolerant B cells but not
with tolerant B cells lacking the B7.2 transgene (Fig. 4 b).
Additionally, the TNFR family member, OX40, was in-
duced on T cells stimulated overnight in vitro with B7.21
tolerant B cells but not with tolerant B cells without the
B7.2 transgene. The selective induction of OX40 on T
cells by B7.21 tolerant B cells may be particularly relevant
to autoimmunity, as OX40 has been implicated in the
clonal expansion of B cell foci in the T zone (27), the pri-
mary site of clonal expansion and autoantibody production
in MRL-lpr/lpr mice (5). Thus, selectively restoring B7.2
expression to tolerant B cells altered the cytokine gene in-
duction profile in collaborating T cells to include a range of
mitogenic and potentially antiapoptotic cytokines.
Figure 2. B7.2 prevents FasL-mediated deletion and promotes prolifer-
ation of tolerant B cells upon interaction with antigen-specific T cells. (a)
Purified B7.21 or control tolerant B cells were adoptively transferred into
irradiated non-tg recipients alone or with purified 1/1 or gld/1 TCR-tg
CD41 T cells. 5 d after transfer, HEL-binding B cells were enumerated
flow cytometrically in spleens from recipient mice. Means are shown for
all groups. SD is indicated for groups of three mice; values for individual
mice are shown for other groups. Horizontal line, Background staining in
negative control animals injected with media only. (b–d) The surviving
transferred B cells had become activated as measured by cell size (b, For-
ward Scatter), recovery of surface IgM (c), and increased expression of Fas (d).
Figure 3. B7.2 provokes plasma cell differentiation and high-rate au-
toantibody secretion by tolerant B cells in the presence of antigen-specific
T cells and continuous exposure to antigen. Purified naive or tolerant B
cells with or without the B7.2 transgene were mixed with purified 1/1
or gld/1 CD41 non-tg or TCR-tg T cells and adoptively transferred into
non-tg (No HEL) or HEL-tg (Self-HEL in Blood) recipients. 5 d later,
spleens from recipient mice were analyzed flow cytometrically to enu-
merate the number and phenotype of transferred HEL-binding B cells
and by spot ELISA to determine the number of cells secreting HEL-spe-
cific antibody in each recipient. (a) Numbers of HEL-binding B cells (top)
and antibody-secreting cells (bottom) in the spleens of individual adoptive
transfer recipients with (right) and without (left) self-HEL in the blood.
Means are shown for all groups. SD is indicated for groups of three mice;
values for individual mice are shown for other groups. Horizontal line,
Background staining in negative control animals injected with RPMI
only. (b) Expression of the plasma cell surface marker, Syndecan, on
B7.21 tolerant B cells 5 d after transfer with 1/1 TCR-tg T cells into
recipients with no circulating HEL (Non-tg; thin lines) or in recipients with
HEL continuously present as a self-antigen in blood (HEL-tg; thick lines).
The histograms show staining for Syndecan on gated IgMa1B2201 cells in
the spleen.656 Repression of B7.2 on Autoreactive B Cells Prevents Autoimmunity
Discussion
The findings here demonstrate that selectively restoring
B7.2 expression on otherwise self-tolerant B cells is sufficient
to switch their fate from peripheral deletion to large-scale
proliferation and autoantibody secretion during interactions
with specific CD41 T cells. Of the many early signals and re-
sponses to BCR engagement that are repressed or altered in
tolerant B cells (12–14), the data here single out repression of
the B7.2 response as being necessary to allow peripheral tol-
erance by FasL/Fas-mediated clonal abortion. The findings
raise interesting questions about how B7.2 switches the out-
come of interactions between tolerant B and T cells, and
highlight the regulation of B7.2 in B cells as a key process
that may be dysregulated by inherited or acquired triggers to
systemic autoimmune disease.
Three possible mechanisms may in principle explain
how dysregulated expression of B7.2 on tolerant B cells
switches the outcome of interactions with autoantigen-spe-
cific T cells from deletion to autoimmunity. First, it is pos-
sible that self-reactive B cells maturing in a B7.2-tg mouse
do not become functionally tolerant in the usual way. This
possibility is ruled out by the data in Fig. 1, which show
that the B7.2 transgene does not interfere with the BCR
modulation and desensitization that characterizes HEL tol-
erant B cells, nor with the acquisition of sensitivity to Fas-
induced apoptosis after activation by CD40 in vitro. The
possibility that a minor subset of nontolerized B cells could
be present in the B7.21-tg mice and account for the large
autoantibody response after transfer with T cells is excluded
by the fact that the magnitude of the response is compara-
ble to that of B7.21 or B7.22 naive B cells, where all of the
B cells are nontolerant (Fig. 3 a). The number of B cells
transferred in these experiments is well below the saturating
dose, so that even a 5–10% subset of nontolerant cells in
the B7.21 tolerant inoculum would be expected to mount
a 10–20-fold reduced response.
Second, it is possible that B7.2 displayed on tolerant B
cells engages CD28 on interacting T cells and transmits a
retrograde signal into the B cell that blocks Fas-induced ap-
optosis and promotes proliferation and differentiation. The
possibility of signal transduction by B7.2 has been raised
previously, based on the presence of potential sites for pro-
tein kinase C phosphorylation (18). Indeed, an anti-B7.2
antibody has been reported to enhance B cell proliferation
and differentiation (28). On the other hand, antibodies or
soluble CD28-Fc or cytotoxic T lymphocyte–associated
antigen 4 (CTLA4)-Fc ligands to B7.2 have not been ob-
served to be mitogenic for B cells (18, 20), nor do they
protect against Fas-mediated apoptosis (29).
The third interpretation for the effect of B7.2 is that it
transmits a costimulus through CD28 in the T cell that al-
ters the spectrum of cytokines/cell surface molecules made
and displayed to the B cell, and these cytokines in turn
promote B cell mitosis and block Fas-induced deletion.
This conclusion is supported by the data in Fig. 4 and in
the literature. Fig. 4 shows that dysregulated expression of
B7.2 on tolerant B cells induces mRNAs for IL-2 and IL-4
in the T cells, and triggers surface expression of the TNFR
homologue, OX40. IL-2 and IL-4 are potent mitogens for
B cells (30), and OX40 is implicated in driving prolifera-
tion of B cells in the T zone by engaging OX40L on the
surface of B cells (31). In addition to promoting mitogene-
sis, IL-4 has also been shown to inhibit the sensitization
of CD40-activated B cells to Fas-induced apoptosis (11,
24–26). Indeed, HEL tolerant B cells are protected from
Fas-induced apoptosis by IL-4 in vitro (26). Interestingly,
transgenic mice that express IL-4 constitutively develop a
systemic autoantibody syndrome reminiscent of MRL-lpr/
lpr mice, consistent with the notion that it blocks Fas-medi-
ated peripheral tolerance (32). The failure of Fas-mediated
Figure 4. Different cytokine genes are induced in the T cells as a result
of B7.2 expression on tolerant B cells. (a and b) Purified B7.21 or control
tolerant B cells were cultured with equal numbers of purified CD41 T
cells from non-tg or 3A9 TCR-tg mice. Cells were harvested, and RNA
was prepared after 16 (a) and 30 h (b). The RNA was converted to
cDNA, and samples were normalized to each other for HPRT concentra-
tion by titrating each cDNA against a known concentration of competitor
plasmid for HPRT by competitive PCR with HPRT-specific primers.
When cDNAs were normalized so as to produce less than twofold differ-
ences in the amount of HPRT PCR product, they were analyzed by
competitive PCR for transcripts encoding IL-2, FasL, CD40L, and IL-4.
The PCR products from the exogenously added competitor plasmid (C)
and the sample cDNA (P) are indicated. The relative amounts of each
RNA transcript in the original sample can be estimated by the strength of
signal for each PCR product itself as well as by the reduction in intensity
of the PCR product from the competitor plasmid (reference 23). Due to
low RNA yield in samples with non-tg T cells and the low concentration
of message, competitive PCR for IL-4 was conducted only from samples
which included TCR-tg T cells. The competitive PCRs were repeated
three times in each of two separate experiments with equivalent results to
those shown. (c) Purified 1/1 CD41 T cells were cultured for 30 h
without stimulus, in anti-CD3–coated wells, or with purified B7.21 or
control tolerant B cells. Cells were then analyzed flow cytometrically for
OX40 by staining with OX40L-Fc (thick histograms) or a control Ig (thin
histograms) followed by anti–human Ig conjugated to PE.657 Rathmell et al.
B cell elimination caused by B7.2 was not simply due to
proliferation outstripping FasL-induced death, because
B7.21 B cell proliferation was not increased further when
the T cells were FasL deficient (Figs. 2 a and 3 a).
It is interesting that constitutive expression of B7.1 on B
cells in transgenic mice prevents induction of an antibody re-
sponse (33, 34), raising the possibility that B7.2 and B7.1
have distinct effects during T–B cell interactions. These ef-
fects could in principle be mediated through retrograde sig-
naling via their distinct cytoplasmic regions or through their
differential interactions with their receptors, CD28 and
CTLA4 (18, 35). It is also intriguing that CD40 and IL-4 are
also good inducers of B7.2 on B cells, and B7.2 responses to
these stimuli are not depressed in tolerant B cells in vitro
(12). CD40L from the T cells transmits signals that induce
Fas on tolerant B cells during the sensitization phase preced-
ing Fas-mediated deletion (8), so it might be expected that
this signal would also upregulate B7.2 and block Fas-medi-
ated deletion, as envisaged by Clark and Ledbetter (36). It is
possible that B7.2 induction by CD40L during tolerant
B cell–T cell interactions in vivo is either insufficient in
amount or occurs too late to block deletion. Clearly, it will
be important in the future to understand precisely how B7.2
and other surface molecules regulate both the induction and
the delivery of Th cell molecules to B cells.
In addition to controlling B7.2 display, BCR signaling in
response to antigen also regulates B cell–T cell interactions at
several other levels. BCR signaling alters the migratory
tropism of antigen-binding naive and tolerant B cells so that
they accumulate preferentially in the T zone (1, 37). It is
likely that this occurs by modulating the function of
chemokine receptors such as Burkitt’s lymphoma receptor 1
(BLR-1; reference 38). BCR signaling also induces produc-
tion of chemokines for activated T cells such as macrophage-
inflammatory protein (MIP)-1a and -1b (our unpublished
observations). The combination of these effects appears likely
to steer migration of antigen-binding B and T cells towards
one another. BCR signals also promote cell cycle progres-
sion in their own right. These signaling responses are lost in
tolerant B cells, and thus prevent activation of autoreactive B
cells by T cell–independent antigens (12, 13). Finally, acute
BCR signaling can block transmission of apoptotic signals
from Fas through intrinsic pathways within the B cell (9–11,
24, 39, 40). This intrinsic effect of BCR signaling might work
by altering expression of FLIP/Casper/FLAME/CASH/
I-FLICE (41–45), inhibitor of apoptosis proteins such as ILP
(46) or Bcl-xL (47), and appears to be desensitized in tolerant
B cells (8). It is conceivable that intrinsic regulation of the
Fas pathway by the BCR acts in concert with the regulation
of B7.2 and its effects as shown here, ensuring selective de-
livery of T cell help to the correct B cell targets in a variety
of tissue locations and stages of the immune response.
The requirement for continued exposure to HEL anti-
gen for differentiation of B7.2 tolerant B cells into plasma
cells (Fig. 3) indicates that the BCR also regulates plasma
cell differentiation independently of clonal expansion. There
are several potential explanations for this finding. First, the
altered signaling properties of desensitized BCRs on the
B7.21 tolerant B cell may not provide or may actively inhibit
the necessary signals for differentiation of plasma cells (12, 13).
However, as the B7.1 tolerant B cells become activated and
proliferate, their receptors are upregulated, an indication that
they are no longer desensitized. Additional antigen at this
point might then provide the appropriate differentiation signals
either within B cells or by providing additional costimulation
to T cells. Second, the presence of antigen has been shown to
alter patterns of B cell migration (1, 2, 48, 49). Therefore, an-
tigen exposure may cause B or T cells to migrate to micro-
environments conducive to B cell differentiation. Finally, tol-
erant B cells transferred into antigen-free recipient mice carry a
finite supply of antigen and antigenic peptides with which to
directly interact with antigen-specific T cells. Additional anti-
gen may allow for stronger or repeated interactions of T cells
with the B cells or other antigen-presenting cells.
The findings described here illuminate the importance of
regulating B7.2 expression on B cells to ensure peripheral
tolerance. Several studies have shown that systemic autoim-
munity can be inhibited by blocking the interactions of
B7.1 and B7.2 with their receptors, CD28 and CTLA4
(18, 20), but do not define which cells must express B7.1
or B7.2 for autoimmunity. The experiments described here
demonstrate that in the presence of nontolerant T cells, the
expression of B7.2 on self-reactive B cells is sufficient to
cause systemic autoimmunity. B7.2 must be expressed on
the autoreactive cells themselves, as the presence of neigh-
boring cells which induce B7.2 normally does not cause
the proliferation of tolerant B cells (12). The lack of a by-
stander effect is most likely due to directional display of cy-
tokines and mitogenic factors (50). It is notable that dysreg-
ulated expression of B7.2 on self-reactive B cells leads to a
much more extreme reversal of tolerance than that pro-
duced by simple Fas deficiency. Inherited Fas deficiency in
C57BL/6 lpr/lpr mice allows self-reactive B cells to resist
elimination by CD41 T cells, but in this case they are stim-
ulated to proliferate by the T cells to only a limited extent
(references 6 and 8; Figs. 2 and 3). By contrast, the B7.21
tolerant B cells undergo a very large clonal expansion. The
strong effect of B7.2 on peripheral tolerance indicates that
it will be important to define the biochemical pathway
which normally regulates B7.2 expression on self-reactive
B cells. Genetic mutations or polymorphisms in this path-
way will be significant candidates for heritable predisposi-
tion to systemic lupus erythematosus, rheumatoid arthritis,
and other human systemic autoimmune diseases.
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